{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-000584","form_type":"8-K","ticker":"PTHS","cik":"0001919246","company_name":"Pelthos Therapeutics Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.311394+00:00","generated_at":"2026-06-04T10:32:09.976570+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Chromocell launches eye pain program targeting $2.5B market; hires Dr. Simon Chandler","bullets":["NaV1.7 sodium channel program for eye pain; addresses 5M annual U.S. corneal abrasions.","Dr. Simon Chandler hired to lead program; 30+ years ophthalmic drug dev experience (Santen, Allergan).","Program targets acute (corneal abrasion, glaucoma) and chronic (dry eye, neuropathic) indications.","Company believes NaV1.7 platform can treat all eye pain indications, currently under-served."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-000584","json":"https://secwatch.observer/filing/0001753926-24-000584.json","markdown":"https://secwatch.observer/filing/0001753926-24-000584.md","text":"https://secwatch.observer/filing/0001753926-24-000584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000584/0001753926-24-000584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000584/g084141_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:32:09.976570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}